首页 > 最新文献

Journal of cancer research and therapeutics最新文献

英文 中文
A novel EML4–NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib 肺腺癌中的新型EML4-NTRK3融合体对恩替利尼反应剧烈
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-26 DOI: 10.4103/jcrt.jcrt_231_21
Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Parveen Jain, Anurag Mehta, Abhishek Bansal

In-frame fusions in NTRK genes, with intact kinase domain, have been reported to occur at higher frequencies in rare tumors like infantile fibrosarcoma, congenital mesoblastic nephroma, and secretory carcinoma, whereas they occur at very low frequencies in common malignancies like NSCLC and colon cancers (0.1%–1%). Despite the rare occurrence, these alterations have gained importance owing to approval of drugs like entrectinib and larotrectinib targeting the kinase domain of the gene. More than 50 fusion partners have been described, and only in-frame fusions result in constitutive ligand-independent kinase activity leading to oncogenesis. The commonly reported NTRK fusions in the lung include SQSTM1–NTRK1, ETV6–NTRK3, and SQSTM1–NTRK3. Detection of these rests on the use of conventional modalities like Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH); however, accurate characterization requires direct sequencing methods. We report an interesting case of an NTRK fusion-positive NSCLC, exhibiting good response to entrectinib.

据报道,具有完整激酶结构域的NTRK基因框架内融合在婴儿纤维肉瘤、先天性间叶性肾瘤和分泌性癌等罕见肿瘤中的发生率较高,而在NSCLC和结肠癌等常见恶性肿瘤中的发生率则非常低(0.1%-1%)。尽管发生率很低,但由于针对该基因激酶结构域的 entrectinib 和 larotrectinib 等药物获得批准,这些改变已变得越来越重要。目前已描述了 50 多种融合伙伴,只有框架内融合才会导致构成性配体依赖性激酶活性,从而导致肿瘤发生。肺部常见的 NTRK 融合包括 SQSTM1-NTRK1、ETV6-NTRK3 和 SQSTM1-NTRK3。这些融合的检测依赖于免疫组化(IHC)和荧光原位杂交(FISH)等传统方法;然而,准确的特征描述需要直接测序方法。我们报告了一例有趣的NTRK融合阳性NSCLC病例,该患者对恩替替尼(entrectinib)治疗反应良好。
{"title":"A novel EML4–NTRK3 fusion in lung adenocarcinoma with dramatic response to entrectinib","authors":"Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Parveen Jain, Anurag Mehta, Abhishek Bansal","doi":"10.4103/jcrt.jcrt_231_21","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_231_21","url":null,"abstract":"<p>In-frame fusions in <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">NTRK</em> genes, with intact kinase domain, have been reported to occur at higher frequencies in rare tumors like infantile fibrosarcoma, congenital mesoblastic nephroma, and secretory carcinoma, whereas they occur at very low frequencies in common malignancies like NSCLC and colon cancers (0.1%–1%). Despite the rare occurrence, these alterations have gained importance owing to approval of drugs like entrectinib and larotrectinib targeting the kinase domain of the gene. More than 50 fusion partners have been described, and only in-frame fusions result in constitutive ligand-independent kinase activity leading to oncogenesis. The commonly reported <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">NTRK</em> fusions in the lung include <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">SQSTM1–NTRK1, ETV6–NTRK3</em>, and <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">SQSTM1–NTRK3</em>. Detection of these rests on the use of conventional modalities like Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH); however, accurate characterization requires direct sequencing methods. We report an interesting case of an <em xmlns:mrws=\"http://webservices.ovid.com/mrws/1.0\">NTRK</em> fusion-positive NSCLC, exhibiting good response to entrectinib.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"10 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2023-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139065488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Histiocytic lesion masquerading as papillary carcinoma thyroid-A case report 伪装成甲状腺乳头状癌的组织细胞病变--病例报告
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-07 DOI: 10.4103/jcrt.jcrt_1376_22
Bipin Kumar, Prerna Chadha, Tanwi Singh, Deepak Kumar

Langerhans cell histiocytosis (LCH) is a rare clonal neoplasm derived from Langerhans-type cells that express CD 1a, langerin, and S 100 on immunohistochemistry. LCH usually involves multiple sites and multiple systems or multiple sites in a single system. Solitary LCH commonly involves the bones (especially the skull), lymph nodes, skin, and lungs. Solitary LCH of the thyroid is an extremely rare disease with a few reported cases in the indexed literature and poses a diagnostic dilemma for both the clinician and pathologist. Histopathology along with ancillary tests forms the gold standard for diagnosis. Surgical resection alone offers a good prognosis once multisystemic involvement has been ruled out. Herein is reported one such case of solitary LCH in a young male patient who remains disease-free after 2 years of follow-up.

朗格汉斯细胞组织细胞增生症(Langerhans cell histiocytosis,LCH)是一种罕见的克隆性肿瘤,由朗格汉斯型细胞衍生而来,这些细胞在免疫组化中表达 CD 1a、朗格素和 S 100。LCH 通常累及多个部位、多个系统或单一系统中的多个部位。单发性LCH通常累及骨骼(尤其是颅骨)、淋巴结、皮肤和肺部。甲状腺单发LCH是一种极为罕见的疾病,在索引文献中仅有几例报道,给临床医生和病理学家带来了诊断难题。组织病理学和辅助检查是诊断的金标准。在排除多系统受累的情况下,单纯手术切除预后良好。本文报告了一例年轻男性单发 LCH 患者,随访 2 年后仍未复发。
{"title":"Histiocytic lesion masquerading as papillary carcinoma thyroid-A case report","authors":"Bipin Kumar, Prerna Chadha, Tanwi Singh, Deepak Kumar","doi":"10.4103/jcrt.jcrt_1376_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1376_22","url":null,"abstract":"<p>Langerhans cell histiocytosis (LCH) is a rare clonal neoplasm derived from Langerhans-type cells that express CD 1a, langerin, and S 100 on immunohistochemistry. LCH usually involves multiple sites and multiple systems or multiple sites in a single system. Solitary LCH commonly involves the bones (especially the skull), lymph nodes, skin, and lungs. Solitary LCH of the thyroid is an extremely rare disease with a few reported cases in the indexed literature and poses a diagnostic dilemma for both the clinician and pathologist. Histopathology along with ancillary tests forms the gold standard for diagnosis. Surgical resection alone offers a good prognosis once multisystemic involvement has been ruled out. Herein is reported one such case of solitary LCH in a young male patient who remains disease-free after 2 years of follow-up.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"237 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141519648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantum dots in noninvasive imaging of oral squamous cell carcinomas: A scoping literature review 量子点在口腔鳞状细胞癌无创成像中的应用:范围性文献综述
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-05 DOI: 10.4103/jcrt.jcrt_2203_21
Bhagyashree Shetty, Rashmi S. Chauhan, Sunnypriyatham Tirupathi, Nene Krishnapriya, Lalit Patil, Nilesh Rathi

The current scoping review’s objective was to outline existing applications, recent breakthroughs, and quantum dots’ applicability in imaging of oral squamous cell cancer. Quantum dots are nanometric semiconductor crystals with customizable optical characteristics and intense, stable fluorescence suited for bioimaging and labeling. We used the Preferred reporting items for systematic reviews and meta-analyses (PRISMA) recommendations for conducting our systematic search. An analysis of the properties and applications of quantum dots in noninvasive detection of oral squamous cell cancer is presented in this study, which comprehensively explores the available evidence. Following searches in the databases PubMed, Ovid SP, and Cochrane using the search terms quantum dots AND oral squamous cell cancer, 55 published publications were chosen for this review. The review identified a total of eight papers that met the criteria. In noninvasive detection of oral squamous cell carcinoma, quantum dots have the potential to offer an array of therapeutic and diagnostic applications. Furthermore, quantum dots emit near-infrared and visible light, which is advantageous in biological imaging since it reduces light dispersion and absorption of tissue. The future may see quantum dots become a popular noninvasive imaging technique for oral squamous cell cancer. The number of studies accessible is quite limited, and further research is required.

本次范围界定审查的目的是概述量子点在口腔鳞状细胞癌成像中的现有应用、最新突破和适用性。量子点是一种纳米半导体晶体,具有可定制的光学特性和强烈、稳定的荧光,适用于生物成像和标记。我们采用系统综述和荟萃分析的首选报告项目(PRISMA)建议进行系统检索。本研究对量子点在口腔鳞状细胞癌无创检测中的特性和应用进行了分析,全面探讨了现有证据。在使用量子点和口腔鳞状细胞癌这两个检索词对 PubMed、Ovid SP 和 Cochrane 等数据库进行检索后,本综述选择了 55 篇已发表的论文。综述共发现 8 篇符合标准的论文。在口腔鳞状细胞癌的无创检测方面,量子点具有提供一系列治疗和诊断应用的潜力。此外,量子点还能发射近红外和可见光,这在生物成像中是有利的,因为它能减少光的色散和组织的吸收。未来,量子点可能会成为口腔鳞状细胞癌的一种流行的无创成像技术。目前可获得的研究数量非常有限,还需要进一步的研究。
{"title":"Quantum dots in noninvasive imaging of oral squamous cell carcinomas: A scoping literature review","authors":"Bhagyashree Shetty, Rashmi S. Chauhan, Sunnypriyatham Tirupathi, Nene Krishnapriya, Lalit Patil, Nilesh Rathi","doi":"10.4103/jcrt.jcrt_2203_21","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_2203_21","url":null,"abstract":"<p>The current scoping review’s objective was to outline existing applications, recent breakthroughs, and quantum dots’ applicability in imaging of oral squamous cell cancer. Quantum dots are nanometric semiconductor crystals with customizable optical characteristics and intense, stable fluorescence suited for bioimaging and labeling. We used the Preferred reporting items for systematic reviews and meta-analyses (PRISMA) recommendations for conducting our systematic search. An analysis of the properties and applications of quantum dots in noninvasive detection of oral squamous cell cancer is presented in this study, which comprehensively explores the available evidence. Following searches in the databases PubMed, Ovid SP, and Cochrane using the search terms quantum dots AND oral squamous cell cancer, 55 published publications were chosen for this review. The review identified a total of eight papers that met the criteria. In noninvasive detection of oral squamous cell carcinoma, quantum dots have the potential to offer an array of therapeutic and diagnostic applications. Furthermore, quantum dots emit near-infrared and visible light, which is advantageous in biological imaging since it reduces light dispersion and absorption of tissue. The future may see quantum dots become a popular noninvasive imaging technique for oral squamous cell cancer. The number of studies accessible is quite limited, and further research is required.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"15 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early endometrial carcinoma: Experience and outcomes. 早期子宫内膜癌:经验和结果。
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-01 DOI: 10.4103/jcrt.jcrt_920_21
Priyanka Goel, Vikram Singh, Rakesh Sharma, Debashish Chaudhary, Abhishek Chatterjee, Tapas Dora, Sankalp Sancheti, Alok Goel, Sachin Khandelwal, Akash Pramod Sali, Harpreet Kaur, Arvind Guru, Rakesh Kapoor

Aim: Endometrial carcinoma (EC) data from India are very sparse. We did a retrospective analysis of our patients registered at this peripheral cancer center based in rural Punjab and studied their outcome.

Materials and methods: Ninety-eight Stage I and II EC patients with endometroid histology registered at our institute from January 2015 to April 2020 were studied for demography, histopathology, treatment received, and outcomes. FIGO 2009 staging and new European Society for Medical Oncology (ESMO) risk group classification was used.

Results: Our patients had a median age of 60 years (range 32-93 years). There were 39 (39.8%), 41 (42.0%), 4 (4.1%), 12 (12.2%) patients in the low risk, intermediate risk (IR), high intermediate risk, and high risk groups, respectively, as per new ESMO risk classification. Two (2.0%) patients had incomplete information to assign them to a particular risk group. Fifty (46.7%) patients underwent complete surgical staging and 54 (50.5%) patients received adjuvant RT. With a median follow-up of 27.0 months, there were 1 locoregional and 2 distant recurrences. There were 8 deaths in total. Three-year overall survival for the entire group is 90.6%.

Conclusions: The risk group determines adjuvant treatment in endometrial cancer. Patients operated at dedicated cancer center tend to have better surgical staging and thus better outcome because of better risk stratification and grouping for adjuvant therapy. IR histology was more common in our group of patients, which is variable as compared to available literature.

目的:印度子宫内膜癌(EC)的数据非常少。我们对在旁遮普农村的外围癌症中心登记的患者进行了回顾性分析,并研究了他们的结果。材料和方法:对2015年1月至2020年4月在我所登记的98例子宫内膜样组织学的I期和II期EC患者的人口学、组织病理学、接受的治疗和结局进行研究。采用FIGO 2009分期和新的欧洲肿瘤医学学会(ESMO)风险组分类。结果:患者的中位年龄为60岁(32-93岁)。按照新的ESMO风险分类,低危组39例(39.8%),中危组41例(42.0%),中高危组4例(4.1%),高危组12例(12.2%)。2例(2.0%)患者的信息不完全,无法将其划分为特定的风险组。50例(46.7%)患者完成了手术分期,54例(50.5%)患者接受了辅助放疗。在27.0个月的中位随访中,有1例局部复发,2例远处复发。共有8人死亡。整个组的三年总体生存率为90.6%。结论:危险人群决定子宫内膜癌的辅助治疗。在专门的癌症中心手术的患者往往有更好的手术分期,从而更好的结果,因为更好的风险分层和分组辅助治疗。IR组织学在本组患者中更为常见,与现有文献相比,这是可变的。
{"title":"Early endometrial carcinoma: Experience and outcomes.","authors":"Priyanka Goel,&nbsp;Vikram Singh,&nbsp;Rakesh Sharma,&nbsp;Debashish Chaudhary,&nbsp;Abhishek Chatterjee,&nbsp;Tapas Dora,&nbsp;Sankalp Sancheti,&nbsp;Alok Goel,&nbsp;Sachin Khandelwal,&nbsp;Akash Pramod Sali,&nbsp;Harpreet Kaur,&nbsp;Arvind Guru,&nbsp;Rakesh Kapoor","doi":"10.4103/jcrt.jcrt_920_21","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_920_21","url":null,"abstract":"<p><strong>Aim: </strong>Endometrial carcinoma (EC) data from India are very sparse. We did a retrospective analysis of our patients registered at this peripheral cancer center based in rural Punjab and studied their outcome.</p><p><strong>Materials and methods: </strong>Ninety-eight Stage I and II EC patients with endometroid histology registered at our institute from January 2015 to April 2020 were studied for demography, histopathology, treatment received, and outcomes. FIGO 2009 staging and new European Society for Medical Oncology (ESMO) risk group classification was used.</p><p><strong>Results: </strong>Our patients had a median age of 60 years (range 32-93 years). There were 39 (39.8%), 41 (42.0%), 4 (4.1%), 12 (12.2%) patients in the low risk, intermediate risk (IR), high intermediate risk, and high risk groups, respectively, as per new ESMO risk classification. Two (2.0%) patients had incomplete information to assign them to a particular risk group. Fifty (46.7%) patients underwent complete surgical staging and 54 (50.5%) patients received adjuvant RT. With a median follow-up of 27.0 months, there were 1 locoregional and 2 distant recurrences. There were 8 deaths in total. Three-year overall survival for the entire group is 90.6%.</p><p><strong>Conclusions: </strong>The risk group determines adjuvant treatment in endometrial cancer. Patients operated at dedicated cancer center tend to have better surgical staging and thus better outcome because of better risk stratification and grouping for adjuvant therapy. IR histology was more common in our group of patients, which is variable as compared to available literature.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 Supplement","pages":"S0"},"PeriodicalIF":1.3,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9417710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study. 高龄对三阴性乳腺癌患者预后的影响:一项监测、流行病学和基于最终结果的研究
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-01 DOI: 10.4103/jcrt.jcrt_90_21
Haosheng Tan, Deyuan Fu

Introduction: Age at diagnosis has shown significant effect on the prognosis in breast cancer patients. However, whether age is an independent risk factor remains controversial. Furthermore, population-based estimates of age on the prognosis impact in triple-negative breast cancer are still lacking. The aim of this study was to analyze the influence of age and other factors on the prognosis and survival of triple-negative breast cancer patients.

Materials and methods: We used the surveillance, epidemiology, and end results program data from 2011 to 2014. A retrospective cohort study was conducted to investigate prognosis factors in triple-negative breast cancer. Patients were divided into two groups according to age at diagnosis: 75 + years (the elderly patients) and < 75 years (reference group). The clinicopathologic characteristics of different age groups were compared using Chi-square tests. Overall survival (OS) and breast cancer-specific survival were analyzed using the Kaplan-Meier method. Prognostic factors were compared using the Cox proportional hazards model. We also analyzed the difference of distant metastasis at initial diagnosis on every group.

Results: A total of 21,429 triple-negative breast cancer patients were included in our study. The mean breast cancer-specific survival time of triple-negative breast cancer was 70.5 months for the reference group and 62.4 months for the elderly group. Survival analysis showed that the breast cancer-specific survival rate was 78.9% for the reference group and 67.4% for the elderly group. The mean OS time was 69.0 months for the reference group and 52.3 months for the elderly group. The 5-year OS of triple-negative breast cancer patients was 76.4% for the reference group and 51.3% for the elderly group. The prognosis of elderly patients is much poor than reference group. Univariate Cox regression analysis showed that age, race, marital status, histological grade, stage, T, N, M, surgery, radiotherapy, and chemotherapy were risk factors for triple-negative breast cancer (TNBC) (P < 0.05). Multivariate Cox regression analysis showed that age, race, marital status, histological grade, stage, T, N, M, surgery, radiotherapy, and chemotherapy were independent risk factors for TNBC (P < 0.05).

Conclusions: Age is an independent risk factor for the prognosis of TNBC patients. Elderly triple-negative breast cancer patients displayed obvious lower 5-year survival rate compared to reference group, even though they have better grade stage, minor tumor, less lymph node metastasis. The lower rate of marital status, radiotherapy, chemotherapy, surgery, and higher rate of metastasis at diagnosis must contribute to their poor outcome.

导读:乳腺癌患者的诊断年龄对预后有显著影响。然而,年龄是否是一个独立的风险因素仍然存在争议。此外,基于人群的年龄对三阴性乳腺癌预后影响的估计仍然缺乏。本研究旨在分析年龄等因素对三阴性乳腺癌患者预后及生存的影响。材料和方法:我们使用2011 - 2014年监测、流行病学和最终结果项目数据。回顾性队列研究探讨三阴性乳腺癌的预后因素。患者根据诊断年龄分为两组:75岁以上(老年患者)和< 75岁(对照组)。采用卡方检验比较不同年龄组的临床病理特征。采用Kaplan-Meier法分析总生存期(OS)和乳腺癌特异性生存期。预后因素采用Cox比例风险模型进行比较。我们还分析了各组初诊时远处转移的差异。结果:本研究共纳入21429例三阴性乳腺癌患者。三阴性乳腺癌的平均乳腺癌特异性生存时间,参照组为70.5个月,老年组为62.4个月。生存分析显示,对照组乳腺癌特异性生存率为78.9%,老年组为67.4%。对照组平均OS时间为69.0个月,老年组平均OS时间为52.3个月。三阴性乳腺癌患者5年OS,参照组为76.4%,老年组为51.3%。老年患者预后明显差于对照组。单因素Cox回归分析显示,年龄、种族、婚姻状况、组织学分级、分期、T、N、M、手术、放疗、化疗是三阴性乳腺癌(TNBC)的危险因素(P < 0.05)。多因素Cox回归分析显示,年龄、种族、婚姻状况、组织学分级、分期、T、N、M、手术、放疗、化疗是TNBC的独立危险因素(P < 0.05)。结论:年龄是影响TNBC患者预后的独立危险因素。老年三阴性乳腺癌患者虽然分期较好,肿瘤较小,淋巴结转移较少,但其5年生存率明显低于对照组。较低的婚姻状况、放疗、化疗、手术率和诊断时较高的转移率必然是导致其预后不良的原因。
{"title":"Influence of advanced age on the prognosis of triple-negative breast cancer patients: A surveillance, epidemiology, and end results-based study.","authors":"Haosheng Tan,&nbsp;Deyuan Fu","doi":"10.4103/jcrt.jcrt_90_21","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_90_21","url":null,"abstract":"<p><strong>Introduction: </strong>Age at diagnosis has shown significant effect on the prognosis in breast cancer patients. However, whether age is an independent risk factor remains controversial. Furthermore, population-based estimates of age on the prognosis impact in triple-negative breast cancer are still lacking. The aim of this study was to analyze the influence of age and other factors on the prognosis and survival of triple-negative breast cancer patients.</p><p><strong>Materials and methods: </strong>We used the surveillance, epidemiology, and end results program data from 2011 to 2014. A retrospective cohort study was conducted to investigate prognosis factors in triple-negative breast cancer. Patients were divided into two groups according to age at diagnosis: 75 + years (the elderly patients) and < 75 years (reference group). The clinicopathologic characteristics of different age groups were compared using Chi-square tests. Overall survival (OS) and breast cancer-specific survival were analyzed using the Kaplan-Meier method. Prognostic factors were compared using the Cox proportional hazards model. We also analyzed the difference of distant metastasis at initial diagnosis on every group.</p><p><strong>Results: </strong>A total of 21,429 triple-negative breast cancer patients were included in our study. The mean breast cancer-specific survival time of triple-negative breast cancer was 70.5 months for the reference group and 62.4 months for the elderly group. Survival analysis showed that the breast cancer-specific survival rate was 78.9% for the reference group and 67.4% for the elderly group. The mean OS time was 69.0 months for the reference group and 52.3 months for the elderly group. The 5-year OS of triple-negative breast cancer patients was 76.4% for the reference group and 51.3% for the elderly group. The prognosis of elderly patients is much poor than reference group. Univariate Cox regression analysis showed that age, race, marital status, histological grade, stage, T, N, M, surgery, radiotherapy, and chemotherapy were risk factors for triple-negative breast cancer (TNBC) (P < 0.05). Multivariate Cox regression analysis showed that age, race, marital status, histological grade, stage, T, N, M, surgery, radiotherapy, and chemotherapy were independent risk factors for TNBC (P < 0.05).</p><p><strong>Conclusions: </strong>Age is an independent risk factor for the prognosis of TNBC patients. Elderly triple-negative breast cancer patients displayed obvious lower 5-year survival rate compared to reference group, even though they have better grade stage, minor tumor, less lymph node metastasis. The lower rate of marital status, radiotherapy, chemotherapy, surgery, and higher rate of metastasis at diagnosis must contribute to their poor outcome.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 Supplement","pages":"S0"},"PeriodicalIF":1.3,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9417711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Unusual presentation of cribriform adenocarcinoma of salivary glands: A case report. 涎腺筛状腺癌的异常表现:1例报告。
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-01 DOI: 10.4103/jcrt.jcrt_411_22
Noura M Kamal, Mohamed F Nahla, Sarah A M Mahmoud

According to the last edition of the World Health Organization classification, cribriform adenocarcinoma of salivary glands (CASGs) was considered a variant of polymorphus adenocarcinoma although many authors proposed CASG as a distinct neoplasm. The aim of this study was to report an unusual presentation of CASG in the buccal mucosa of a 63-year-old male patient that showed signs of encapsulation and no evidence of lymph node metastasis. The lesion was composed of lobules of tumoral cells arranged in solid nests, sheets, papillary, and cribriform or glomeruloid patterns. Most of the peripheral cells show palisaded arrangement with peripheral clefting from the adjacent stroma. Surgical resection of the lesion was done and further neck dissection was recommended.

根据世界卫生组织最新版的分类,尽管许多作者认为筛状腺癌(CASG)是一种不同的肿瘤,但它被认为是多形腺癌的一种变体。本研究的目的是报告一名63岁男性患者颊粘膜CASG的不寻常表现,表现出包封的迹象,没有淋巴结转移的证据。病变由肿瘤细胞小叶组成,排列成实巢状、片状、乳头状、筛网状或肾小球状。大多数外周细胞呈栅栏状排列,与相邻间质分离。手术切除病变,并建议进一步颈部清扫。
{"title":"Unusual presentation of cribriform adenocarcinoma of salivary glands: A case report.","authors":"Noura M Kamal,&nbsp;Mohamed F Nahla,&nbsp;Sarah A M Mahmoud","doi":"10.4103/jcrt.jcrt_411_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_411_22","url":null,"abstract":"<p><p>According to the last edition of the World Health Organization classification, cribriform adenocarcinoma of salivary glands (CASGs) was considered a variant of polymorphus adenocarcinoma although many authors proposed CASG as a distinct neoplasm. The aim of this study was to report an unusual presentation of CASG in the buccal mucosa of a 63-year-old male patient that showed signs of encapsulation and no evidence of lymph node metastasis. The lesion was composed of lobules of tumoral cells arranged in solid nests, sheets, papillary, and cribriform or glomeruloid patterns. Most of the peripheral cells show palisaded arrangement with peripheral clefting from the adjacent stroma. Surgical resection of the lesion was done and further neck dissection was recommended.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 Supplement","pages":"S0"},"PeriodicalIF":1.3,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9417713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discordance of estrogen and progesterone receptors after neoadjuvant chemotherapy in locally advanced breast cancer. 局部晚期乳腺癌新辅助化疗后雌激素和孕激素受体的不一致。
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-01 DOI: 10.4103/jcrt.jcrt_873_21
Surabhi Gupta, Alvin Anto, Juhi Singhal, Pooja Agarwal

Aims and objective: This study aimed to compare hormone receptor (HR) status before and after neoadjuvant chemotherapy that is discordance in locally advanced breast cancer patients, which are amenable for surgery. The secondary objective was to study the correlation between tumor response and HR expression.

Materials and methods: The duration of the study was from August 2018 to December 2020. A total of 23 patients were selected as per certain inclusion criteria. American Society of Clinical Oncologys methodology was used to analyze estrogen receptor (ER) and progesterone receptor (PR) status of histopathology specimen. For study purposes, patients were classified into four groups after core biopsy of breast lump and after definitive surgery (post-NACT (neoadjuvant chemotherapy)) - Group A (ER+, PR+), Group B (ER+, PR-), Group C (ER-, PR+), and Group D (ER-, PR-).

Results: ER discordance was found to be (2/23) 8.69% (P value 0.76). PR discordance was (4/23) 17.39%. PR discordance was found to be higher than ER discordance. Changes in staining patterns in ERs were seen in 14 patients (93.33%). Changes in staining percentage in PRs were seen in eight patients (80%). It was found that both receptor-positive and negative diseases had an equal proportion of stable disease.

Conclusion: From the study, it is noted that performing ER PR study twice (before and after chemotherapy) is necessary as discordance is noted and this may impact the further treatment strategy.

目的:本研究旨在比较适合手术的局部晚期乳腺癌患者在新辅助化疗前后激素受体(HR)状态的不一致性。次要目的是研究肿瘤反应与HR表达的相关性。材料与方法:研究时间为2018年8月至2020年12月。按照一定的纳入标准,共选择23例患者。采用美国临床肿瘤学会的方法分析组织病理标本的雌激素受体(ER)和孕激素受体(PR)状态。为了研究目的,患者在乳房肿块核心活检和最终手术后分为四组(nact(新辅助化疗)后)- A组(ER+, PR+), B组(ER+, PR-), C组(ER-, PR+)和D组(ER-, PR-)。结果:ER不一致性为(2/23)8.69% (P值0.76)。PR不一致性为(4/23)17.39%。PR不一致高于ER不一致。14例(93.33%)患者内窥镜染色改变。8例(80%)患者pr染色百分比发生变化。结果发现,受体阳性和阴性疾病在稳定型疾病中所占比例相等。结论:从研究中可以看出,在化疗前后进行两次ER PR研究是必要的,因为发现了不一致,这可能会影响进一步的治疗策略。
{"title":"Discordance of estrogen and progesterone receptors after neoadjuvant chemotherapy in locally advanced breast cancer.","authors":"Surabhi Gupta,&nbsp;Alvin Anto,&nbsp;Juhi Singhal,&nbsp;Pooja Agarwal","doi":"10.4103/jcrt.jcrt_873_21","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_873_21","url":null,"abstract":"<p><strong>Aims and objective: </strong>This study aimed to compare hormone receptor (HR) status before and after neoadjuvant chemotherapy that is discordance in locally advanced breast cancer patients, which are amenable for surgery. The secondary objective was to study the correlation between tumor response and HR expression.</p><p><strong>Materials and methods: </strong>The duration of the study was from August 2018 to December 2020. A total of 23 patients were selected as per certain inclusion criteria. American Society of Clinical Oncologys methodology was used to analyze estrogen receptor (ER) and progesterone receptor (PR) status of histopathology specimen. For study purposes, patients were classified into four groups after core biopsy of breast lump and after definitive surgery (post-NACT (neoadjuvant chemotherapy)) - Group A (ER+, PR+), Group B (ER+, PR-), Group C (ER-, PR+), and Group D (ER-, PR-).</p><p><strong>Results: </strong>ER discordance was found to be (2/23) 8.69% (P value 0.76). PR discordance was (4/23) 17.39%. PR discordance was found to be higher than ER discordance. Changes in staining patterns in ERs were seen in 14 patients (93.33%). Changes in staining percentage in PRs were seen in eight patients (80%). It was found that both receptor-positive and negative diseases had an equal proportion of stable disease.</p><p><strong>Conclusion: </strong>From the study, it is noted that performing ER PR study twice (before and after chemotherapy) is necessary as discordance is noted and this may impact the further treatment strategy.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 Supplement","pages":"S0"},"PeriodicalIF":1.3,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9424666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The unexpected effect of the combination of lapatinib and capecitabin in cranial metastasis. 拉帕替尼联合卡培他滨治疗颅内转移的意外效果。
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-01 DOI: 10.4103/jcrt.jcrt_1440_21
Ahmet Gulmez

Cranial metastasis (CM) is a serious problem in breast cancer patients. In patients with CM, quality of life is adversely affected and the survival of patients is reduced. It is also very difficult to manage breast cancer patients with cranial metastases whose life expectancy is generally 1 year or less. There is no case report in the literature of CM with more than 5 years of progression-free survival (PFS) with oncological treatment. I presented a rare case about the widespread CM developed with tamoxifen treatment in an advanced breast cancer patient who completed chemotherapy and radiotherapy after primary surgery. Systemic treatment was started as a combination of capecitabine and lapatinib after whole-brain radiotherapy was applied to the patient with extensive CM. At the end of about 3 years, there is complete response of cranial metastases, and PFS is over 5 years. The treatment was well tolerated, and she is still being followed up in the 74th month of this treatment without recurrence. There are no case reports of HER-2-positive breast cancer patients with such widespread cranial metastases in complete remission at 34 months of systemic therapy and 74 months of PFS. Our article is unique in this respect. It should be kept in mind that it is not appropriate to change the treatment plan of patients with only one case report. Although the options have increased with the use of new generation antihuman epidermal growth factor receptor 2 treatments, lapatinib can be a very effective treatment tool in selected patients.

脑转移(CM)是乳腺癌患者的一个严重问题。在CM患者中,生活质量受到不利影响,患者生存率降低。对于那些预期寿命一般为1年或更短的颅骨转移的乳腺癌患者来说,治疗也非常困难。文献中没有肿瘤治疗后无进展生存期(PFS)超过5年的CM病例报告。我报告了一个罕见的病例,在原发性手术后完成化疗和放疗的晚期乳腺癌患者中,他莫昔芬治疗后出现了广泛的CM。广泛CM患者全脑放疗后,开始全身治疗卡培他滨和拉帕替尼联合治疗。术后3年左右,颅脑转移完全缓解,PFS超过5年。治疗耐受性良好,患者在治疗的第74个月仍在随访,未复发。目前还没有her -2阳性乳腺癌患者在接受34个月的全身治疗和74个月的PFS后出现如此广泛的颅脑转移而完全缓解的病例报告。我们的商品在这方面是独一无二的。需要注意的是,只有一个病例报告的患者不适合改变治疗方案。尽管随着新一代抗人表皮生长因子受体2治疗的使用,选择增加了,但拉帕替尼在某些患者中可能是一种非常有效的治疗工具。
{"title":"The unexpected effect of the combination of lapatinib and capecitabin in cranial metastasis.","authors":"Ahmet Gulmez","doi":"10.4103/jcrt.jcrt_1440_21","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_1440_21","url":null,"abstract":"<p><p>Cranial metastasis (CM) is a serious problem in breast cancer patients. In patients with CM, quality of life is adversely affected and the survival of patients is reduced. It is also very difficult to manage breast cancer patients with cranial metastases whose life expectancy is generally 1 year or less. There is no case report in the literature of CM with more than 5 years of progression-free survival (PFS) with oncological treatment. I presented a rare case about the widespread CM developed with tamoxifen treatment in an advanced breast cancer patient who completed chemotherapy and radiotherapy after primary surgery. Systemic treatment was started as a combination of capecitabine and lapatinib after whole-brain radiotherapy was applied to the patient with extensive CM. At the end of about 3 years, there is complete response of cranial metastases, and PFS is over 5 years. The treatment was well tolerated, and she is still being followed up in the 74th month of this treatment without recurrence. There are no case reports of HER-2-positive breast cancer patients with such widespread cranial metastases in complete remission at 34 months of systemic therapy and 74 months of PFS. Our article is unique in this respect. It should be kept in mind that it is not appropriate to change the treatment plan of patients with only one case report. Although the options have increased with the use of new generation antihuman epidermal growth factor receptor 2 treatments, lapatinib can be a very effective treatment tool in selected patients.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 Supplement","pages":"S0"},"PeriodicalIF":1.3,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9424669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transformation of ameloblastoma to ameloblastic carcinoma in a 10-year-old child. 10岁儿童成釉细胞瘤向成釉细胞癌的转变。
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-01 DOI: 10.4103/jcrt.jcrt_282_22
Md Ali Osama, Seema Rao, Shova Kunvar, Rakesh K Koul, Bheem S Nanda

Ameloblastic carcinoma (AC) is a rare odontogenic malignant epithelial neoplasm of maxillofacial skeleton with a distinct predisposition of the mandible. It can occur in a wide range of age groups, with a sex predilection in males. It can arise either as a de novo lesion or from preexisting ameloblastoma. AC has a high propensity for local recurrence as well as distant metastasis (chiefly lungs), thus requiring an aggressive surgical approach and a strict surveillance. Owing to the rarity of publications describing AC, little is known about this entity in pediatric patients. We report a case of transformation of ameloblastoma into AC in a 10-year-old child.

成釉细胞癌是一种罕见的牙源性恶性上皮肿瘤,多发于下颌骨。它可以发生在广泛的年龄组,以男性为性别偏好。它既可以是新发病变,也可以是先前存在的成釉细胞瘤。AC有很高的局部复发和远处转移(主要是肺)的倾向,因此需要积极的手术方法和严格的监测。由于罕见的出版物描述AC,很少知道这个实体在儿科患者。我们报告一例成釉细胞瘤转化为AC在一个10岁的孩子。
{"title":"Transformation of ameloblastoma to ameloblastic carcinoma in a 10-year-old child.","authors":"Md Ali Osama,&nbsp;Seema Rao,&nbsp;Shova Kunvar,&nbsp;Rakesh K Koul,&nbsp;Bheem S Nanda","doi":"10.4103/jcrt.jcrt_282_22","DOIUrl":"https://doi.org/10.4103/jcrt.jcrt_282_22","url":null,"abstract":"<p><p>Ameloblastic carcinoma (AC) is a rare odontogenic malignant epithelial neoplasm of maxillofacial skeleton with a distinct predisposition of the mandible. It can occur in a wide range of age groups, with a sex predilection in males. It can arise either as a de novo lesion or from preexisting ameloblastoma. AC has a high propensity for local recurrence as well as distant metastasis (chiefly lungs), thus requiring an aggressive surgical approach and a strict surveillance. Owing to the rarity of publications describing AC, little is known about this entity in pediatric patients. We report a case of transformation of ameloblastoma into AC in a 10-year-old child.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 Supplement","pages":"S0"},"PeriodicalIF":1.3,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9425055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anticancer activity of gold nanobioconjugates synthesized from Elephantopus scaber (linn.) leaf extract. 大象叶提取物合成金纳米生物偶联物的抗癌活性研究。
IF 1.3 4区 医学 Q4 ONCOLOGY Pub Date : 2023-04-01 DOI: 10.4103/jcrt.JCRT_1043_20
Ashwini S Shinde, Vijay D Mendhulkar

Introduction: Medicinal plants are the major natural resources for the treatment of human ailments including cancer therapy. The current cancer treatments such as surgery, radiation, and chemotherapy affect normal cells too. Thus, treatments like synthesized nanoscale particles using plant extracts have proven to be potential anticancer agent.

Aim of the study: We hypothesize that the gold nanoparticles (AuNPs) synthesized using Elephantopus scaber hydro-methanolic extract may have anti-cancer activity along with their synergistic counterparts with adriamycin (ADR) on human breast cancer MCF-7: human breast cancer (A-549), human oral cancer (squamous cell carcinoma [SCC]-40), and COLO-205: human colon cancer cell lines.

Materials and methods: The phytosynthesized AuNPs were characterized for ultraviolet-visible (UV-Vis) spectroscopy, nanoparticle tracking analysis (NTA), X-ray diffraction, scanning electron microscopy, transmission electron microscopy (TEM), and Fourier transform infrared (FTIR) analysis. The anticancer ability of the AuNPs against human MCF-7, A-549, SCC-40, and COLO-205 through sulforhodamine B assay has been studied.

Results: The synthesis of AuNPs was confirmed with the UV-Vis spectrophotometer with a peak at 540 nm. The FTIR analysis showed polyphenolic groups were major found to be the reduction and capping agent for AuNPs. According to the results obtained, AuNPs showed good anti-proliferative activity with GI50 <10 μg/ml on MCF-7 cancer cell line. The synergistic effect of AuNPs + ADR was even better for all the four cell lines than that of the AuNPs alone.

Conclusion: The green synthesis of AuNPs is a simple, eco-friendly, and cost-effective method with dominantly spherical morphology ranging from 20 to 40 nm confirmed by NTA and TEM analysis. The study reveals the potent therapeutic value of the AuNPs.

药用植物是治疗包括癌症在内的人类疾病的主要天然资源。目前的癌症治疗方法,如手术、放疗和化疗,也会影响正常细胞。因此,使用植物提取物合成纳米级颗粒等治疗方法已被证明是潜在的抗癌剂。研究目的:我们假设用象皮水甲醇提取物合成的金纳米颗粒(AuNPs)可能与阿霉素(ADR)协同对人乳腺癌MCF-7:人乳腺癌(A-549)、人口腔癌(鳞状细胞癌[SCC]-40)和COLO-205:人结肠癌细胞系具有抗癌活性。材料与方法:利用紫外-可见光谱(UV-Vis)、纳米颗粒跟踪分析(NTA)、x射线衍射、扫描电镜、透射电镜(TEM)和傅里叶变换红外(FTIR)对植物合成的AuNPs进行了表征。通过磺胺B法研究了AuNPs对人MCF-7、A-549、SCC-40和COLO-205的抗癌能力。结果:用紫外可见分光光度计证实了AuNPs的合成,峰在540nm处。FTIR分析表明,多酚基团是aunp的主要还原和封盖剂。结论:经NTA和TEM分析证实,AuNPs的绿色合成以20 ~ 40 nm的球形形态为主,是一种简单、环保、经济的绿色合成方法。该研究揭示了aunp的有效治疗价值。
{"title":"Anticancer activity of gold nanobioconjugates synthesized from <i>Elephantopus scaber</i> (linn.) leaf extract.","authors":"Ashwini S Shinde,&nbsp;Vijay D Mendhulkar","doi":"10.4103/jcrt.JCRT_1043_20","DOIUrl":"https://doi.org/10.4103/jcrt.JCRT_1043_20","url":null,"abstract":"<p><strong>Introduction: </strong>Medicinal plants are the major natural resources for the treatment of human ailments including cancer therapy. The current cancer treatments such as surgery, radiation, and chemotherapy affect normal cells too. Thus, treatments like synthesized nanoscale particles using plant extracts have proven to be potential anticancer agent.</p><p><strong>Aim of the study: </strong>We hypothesize that the gold nanoparticles (AuNPs) synthesized using Elephantopus scaber hydro-methanolic extract may have anti-cancer activity along with their synergistic counterparts with adriamycin (ADR) on human breast cancer MCF-7: human breast cancer (A-549), human oral cancer (squamous cell carcinoma [SCC]-40), and COLO-205: human colon cancer cell lines.</p><p><strong>Materials and methods: </strong>The phytosynthesized AuNPs were characterized for ultraviolet-visible (UV-Vis) spectroscopy, nanoparticle tracking analysis (NTA), X-ray diffraction, scanning electron microscopy, transmission electron microscopy (TEM), and Fourier transform infrared (FTIR) analysis. The anticancer ability of the AuNPs against human MCF-7, A-549, SCC-40, and COLO-205 through sulforhodamine B assay has been studied.</p><p><strong>Results: </strong>The synthesis of AuNPs was confirmed with the UV-Vis spectrophotometer with a peak at 540 nm. The FTIR analysis showed polyphenolic groups were major found to be the reduction and capping agent for AuNPs. According to the results obtained, AuNPs showed good anti-proliferative activity with GI50 <10 μg/ml on MCF-7 cancer cell line. The synergistic effect of AuNPs + ADR was even better for all the four cell lines than that of the AuNPs alone.</p><p><strong>Conclusion: </strong>The green synthesis of AuNPs is a simple, eco-friendly, and cost-effective method with dominantly spherical morphology ranging from 20 to 40 nm confirmed by NTA and TEM analysis. The study reveals the potent therapeutic value of the AuNPs.</p>","PeriodicalId":15208,"journal":{"name":"Journal of cancer research and therapeutics","volume":"19 Supplement","pages":"S0"},"PeriodicalIF":1.3,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9426363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
Journal of cancer research and therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1